| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Carvacrol appears to be slowly absorbed from the intestines in rabbits, as approximately 30% of a 1.5 g dose remained in the gastrointestinal tract 22 hours after administration, and approximately 25% was excreted in the urine. Carvacrol applied to the intact shaved abdominal skin of mice was not absorbed within 2 hours. Metabolism/Metabolites When fed to rabbits, the substituted monophenols thymol and carvacrol, present in plant essential oils, bind with glucuronic acid, acid, and sulfate. Carvacrol is metabolized by binding with glucuronic acid and sulfate. Known human metabolites of carvacrol include (2-methyl-5-prop-2-ylphenyl) hydrogen sulfate and (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(2-methyl-5-prop-2-ylphenoxy)oxacyclohexane-2-carboxylic acid. |
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Oregano (Origanum vulgare) leaves and oil contain carvacrol, thymol, eugenol, and rosmarinic acid. Oregano has been used to treat respiratory and gastrointestinal ailments and has antibacterial properties. Oregano oil has been recommended for treating nipple candidiasis during lactation; however, no clinical studies have confirmed its safety and efficacy. In Turkey, oregano has been used as a galactagogue. Currently, there is no data on whether oregano components are excreted into breast milk, or on the safety and efficacy of oregano for breastfeeding mothers or infants. Oregano and oregano oil are classified as "Generally Recognized As Safe" (GRAS) food ingredients by the U.S. Food and Drug Administration (FDA). Oregano is generally well tolerated, but gastrointestinal upset and allergic skin reactions have been reported in rare cases. Due to a lack of data, breastfeeding women should avoid consuming oregano in amounts exceeding those used as food flavorings. Dietary supplements do not require premarket approval from the U.S. Food and Drug Administration (FDA). Manufacturers are responsible for ensuring product safety but are not required to prove the safety and efficacy of dietary supplements before they are marketed. Dietary supplements may contain multiple ingredients, and the ingredients listed on the label often differ from the actual ingredients or amounts. Manufacturers may commission independent organizations to verify the quality of the product or its ingredients, but this does not guarantee the product's safety and efficacy. Given the above, clinical trial results for one product may not apply to other products. For more detailed information on dietary supplements, please visit other pages on the LactMed website. ◉ Effects on breastfed infants No published information found as of the revision date. ◉ Effects on lactation and breast milk No published information found as of the revision date. |
| References |
|
| Additional Infomation |
Carvacrol is a phenolic compound and a natural monoterpene derivative of p-cymene. It inhibits bacterial growth and is therefore used as a food additive. Carvacrol is a potent activator of transient receptor potential V3 (TRPV3) and A1 (TRPA1) ion channels in the human body. It is used as a volatile oil component, flavoring agent, antibacterial agent, agrochemical, and TRPA1 channel agonist. Carvacrol belongs to the phenolic class of compounds, is a p-menthane monoterpene, and is also a plant-based antifungal agent. It is derived from the hydride of p-cymene. Carvacrol has been reported in Callistemon citrinus, Perilla frutescens, and several other organisms with relevant data. Carvacrol is a metabolite found or produced in Saccharomyces cerevisiae. See also: Oregano leaf oil (partial).
|
| Molecular Formula |
C10H14O
|
|---|---|
| Molecular Weight |
150.22
|
| Exact Mass |
150.104
|
| CAS # |
499-75-2
|
| PubChem CID |
10364
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
237.2±9.0 °C at 760 mmHg
|
| Melting Point |
3-4 °C(lit.)
|
| Flash Point |
106.7±0.0 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.523
|
| LogP |
3.28
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
120
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1=C(C([H])([H])[H])C([H])=C([H])C(=C1[H])C([H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
RECUKUPTGUEGMW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3
|
| Chemical Name |
2-methyl-5-propan-2-ylphenol
|
| Synonyms |
BRN-1860514; Carvacrol; Antioxine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~665.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (16.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6569 mL | 33.2845 mL | 66.5690 mL | |
| 5 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL | |
| 10 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
